These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 17366036)

  • 1. Serum myeloperoxidase in cystic fibrosis patients receiving systemic antibiotics.
    Kohlhoff SA; Köhler E; Sollich V
    Scand J Infect Dis; 2007; 39(2):163-6. PubMed ID: 17366036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamins A and E and pulmonary exacerbations in patients with cystic fibrosis.
    Hakim F; Kerem E; Rivlin J; Bentur L; Stankiewicz H; Bdolach-Abram T; Wilschanski M
    J Pediatr Gastroenterol Nutr; 2007 Sep; 45(3):347-53. PubMed ID: 17873748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Successive courses of intensive therapy in cystic fibrosis (author's transl)].
    Feigelson J; Pecau Y; Gaultier C; Boule M; Høiby N
    Nouv Presse Med; 1981 Mar; 70(12):955-8. PubMed ID: 7208319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in lung function in young cystic fibrosis patients between two courses of intravenous antibiotics against Pseudomonas aeruginosa.
    Béghin L; Michaud L; Loeuille GA; Wizla-Derambure N; Sayah H; Sardet A; Thumerelle C; Deschildre A; Turck D; Gottrand F
    Pediatr Pulmonol; 2009 May; 44(5):464-71. PubMed ID: 19360849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
    Hansen CR; Pressler T; Høiby N
    J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients.
    Worlitzsch D; Rintelen C; Böhm K; Wollschläger B; Merkel N; Borneff-Lipp M; Döring G
    Clin Microbiol Infect; 2009 May; 15(5):454-60. PubMed ID: 19196263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikacin.
    Halacova M; Kotaska K; Kukacka J; Vavrova V; Kuzelova M; Ticha J; Prusa R
    J Clin Pharm Ther; 2008 Aug; 33(4):409-17. PubMed ID: 18613859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection.
    Steinkamp G; Schmitt-Grohe S; Döring G; Staab D; Pfründer D; Beck G; Schubert R; Zielen S
    Respir Med; 2008 Nov; 102(11):1643-53. PubMed ID: 18701270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The approach to Pseudomonas aeruginosa in cystic fibrosis.
    Bendiak GN; Ratjen F
    Semin Respir Crit Care Med; 2009 Oct; 30(5):587-95. PubMed ID: 19760546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden.
    Knudsen PK; Olesen HV; Høiby N; Johannesson M; Karpati F; Laerum BN; Meyer P; Pressler T; Lindblad A;
    J Cyst Fibros; 2009 Mar; 8(2):135-42. PubMed ID: 19157995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anti Pseudomonas aeruginosa antibiotic therapy in cystic fibrosis (exclusion of macrolides)].
    Sermet-Gaudelus I; Ferroni A; Vrielinck S; Lebourgeois M; Chedevergne F; Lenoir G
    Arch Pediatr; 2006 Oct; 13 Suppl 1():S30-43. PubMed ID: 17370394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eradication of early Pseudomonas infection in cystic fibrosis.
    Lee TW
    Chron Respir Dis; 2009; 6(2):99-107. PubMed ID: 19411571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approaches to the treatment of initial Pseudomonas aeruginosa infection in children who have cystic fibrosis.
    Lahiri T
    Clin Chest Med; 2007 Jun; 28(2):307-18. PubMed ID: 17467550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temocillin in cystic fibrosis: a retrospective pilot study.
    Kent L; Bradley JM; France M; Döring G; Carryn S; Bradbury I; Rendall J; Jones A; Elborn JS
    J Cyst Fibros; 2008 Nov; 7(6):551-4. PubMed ID: 18706868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis.
    Latzin P; Fehling M; Bauernfeind A; Reinhardt D; Kappler M; Griese M
    J Cyst Fibros; 2008 Mar; 7(2):142-6. PubMed ID: 17766190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa infections in cystic fibrosis.
    Etherington C; Hall M; Conway S; Peckham D; Denton M
    J Antimicrob Chemother; 2008 Feb; 61(2):425-7. PubMed ID: 18156280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regimens for eradicating early Pseudomonas aeruginosa infection in children do not promote antibiotic resistance in this organism.
    Ho SA; Lee TW; Denton M; Conway SP; Brownlee KG
    J Cyst Fibros; 2009 Jan; 8(1):43-6. PubMed ID: 18829398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation.
    Downey DG; Brockbank S; Martin SL; Ennis M; Elborn JS
    Pediatr Pulmonol; 2007 Aug; 42(8):729-35. PubMed ID: 17588254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody response to Pseudomonas aeruginosa in children with cystic fibrosis.
    Milagres LG; Castro TL; Garcia D; Cruz AC; Higa L; Folescu T; Marques EA
    Pediatr Pulmonol; 2009 Apr; 44(4):392-401. PubMed ID: 19283764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Macrolides, Pseudomonas aeruginosa and cystic fibrosis].
    Guillot M; Amiour M; El Hachem C; Harchaoui S; Ribault V; Paris C
    Arch Pediatr; 2006 Oct; 13 Suppl 1():S48-50. PubMed ID: 17370396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.